Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moALBENDAZOLE (albendazole) by Molecular Devices is synthetic, anthelminthic drug of the class benzimidazole [ see ]. Approved for parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium, cystic hydatid disease of the liver and 4 more indications. First approved in 2020.
Drug data last refreshed 21h ago
synthetic, anthelminthic drug of the class benzimidazole [ see ].
Worked on ALBENDAZOLE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel
Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers After Albendazole Therapy in South Bangka District
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo